Merck

FDA Action Alert: Horizon, Bristol Myers Squibb, Merck, NewLink, Seattle Genetics and Astellas | 3/9/2020

… this vaccine by the FDA represents another important milestone in the global response to Ebola Virus Disease and stands as a tremendous accomplishment by a unique global partnership,” said Roger M. Perlmutter, president of Merck Research Laboratories, at the time. “In acknowledging this event, I wish in particular to recognize the heroic efforts being made by frontline responders to the ongoing outbreak in the Democratic Republic of Congo. We are …

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC) | 3/7/2020

… Plus Chemotherapy Significantly Improved PFS Compared to Chemotherapy Alone in Patients with mTNBC Whose Tumors Expressed PD-L1 (CPS ≥10) Data to be Presented at an Upcoming Medical Congress and Discussed with Regulatory Authorities Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-355 trial investigating KEYTRUDA, Merck ’s anti-PD-1 therapy, in combination with chemotherapy met one of …

Follow Merck:    

Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite | 3/4/2020

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200304005217/en/ “Our goal is to develop new antimalarial treatments that will kill the parasite once it’s present inside the human body, and we’re excited to be working with Merck scientists and other leaders in the field to advance this novel class of compounds that inhibit PMIX and PMX,” said Professor Alan F. Cowman, Ph.D., Deputy …

Merck’s Keytruda builds blood cancer case with head-on win against SeaGen’s Adcetris | FiercePharma | 3/3/2020

Merck’s Keytruda builds blood cancer case with head-on win against SeaGen’s Adcetris by Angus Liu Mar 2, 2020 12:02pm Merck ‘s Keytruda hopes to turn an accelerated FDA nod for refractory classical Hodgkin lymphoma into a full one with a head-to-head win against Seattle Genetics’ Adcetris. (Merck) Merck & Co.’s Keytruda already has an accelerated FDA nod in refractory classical Hodgkin lymphoma. To prove it indeed deserves a …

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) | 3/2/2020

Corporate News Merck ’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Data from Pivotal Phase 3 KEYNOTE-204 Study to be Presented at an Upcoming Medical Meeting and Submitted to Regulatory Authorities Category: Monday, March 2, 2020 6:30 am EST Dateline: NYSE: MRK “Patients with classical Hodgkin lymphoma are generally young and when they do not achieve …

Merck Announces New Data from Broad HIV Program at CROI 2020 | Business Wire | 3/2/2020

… is fueled by our goal to develop meaningful scientific innovations that someday may help people living with HIV,” said Dr. George Hanna, vice president and therapeutic area head of infectious diseases, Global Clinical Development, Merck Research Laboratories. “We look forward to discussing the latest evidence for the clinical potential of our investigational candidates, including islatravir.” Select abstracts in the CROI 2020 program include: Weekly Oral Islatravir Provides Effective PEP Against …

Mercks KEYTRUDA (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) | Financial Buzz | 3/2/2020

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-204 trial evaluating KEYTRUDA, Merck ’s anti-PD-1 therapy, for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) met one of its dual primary endpoints of progression-free survival (PFS). Based on an interim analysis conducted by an independent Data Monitoring Committee (DMC), KEYTRUDA demonstrated a …

Merck & Co. says late-stage study of Keytruda in classical Hodgkin lymphoma hits PFS endpoint | 3/2/2020

… PFS). An interim analysis of the KEYNOTE-204 trial showed that the anti-PD-1 therapy demonstrated a significant and clinically meaningful improvement in PFS compared with Seattle Genetics’ Adcetris (brentuximab vedotin). According to Merck , per the pre-specified analysis plan, the other dual primary endpoint of overall survival was not formally tested at this interim analysis. “These data are strongly supportive of Keytruda’s current indication in cHL and we …

Black History Month — a Time to Reflect and Celebrate at Merck | 2/29/2020

Black History Month — a Time to Reflect and Celebrate at Merck Diversity and inclusion are part of our rich history and fundamental to our future success. In celebration of Black History Month, we highlight employees who have made an impact on our past, present and future. Susan Jenkins Susan Jenkins began a long career at Merck in 1957 when she joined Merck Research Laboratories as one of its first female …

PEDVAXHIB (haemophilus b conjugate vaccine (meningococcal protein conjugate)) injection, suspension [Merck Sharp & Dohme Corp.] | National Institutes of Health | 2/24/2020

… meningitidis outer-membrane protein. Lancet 2: 299-302, 1986. Ahonkhai, V.I., et al: Haemophilus influenzae type b Conjugate Vaccine (Meningococcal Protein Conjugate) (PedvaxHIB TM): Clinical Evaluation. Pediatr 85 (4): 676-681, 1990. Data on file at Merck Research Laboratories. Granoff, D. M., et al: Immunogenicity of Haemophilus influenzae type b polysaccharide—outer membrane protein conjugate vaccine in patients who acquired Haemophilus disease despite previous vaccination with type b polysaccharide vaccine. J. Pediatr …

FDA Rejects Merck’s 6-Week Dosing Schedule for Keytruda | BioSpace | 2/19/2020

… infused over 30 minutes for indications in melanoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, gastric cancer, hepatocellular carcinoma and Merkel cell carcinoma. The agency issued a Complete Response Letter (CRL), which Merck indicates it is reviewing and will discuss their next plans with the FDA. The applications were based on pharmacokinetic modeling and simulation data that the company presented at the 2018 ASCO Annual meeting. They also …

Neurodon Corporation Announces the Addition of John Amatruda, M.D., Former Head of Diabetes and Obesity at Merck & Co, to its Scientific Advisory Board | 2/17/2020

… therapeutics for diabetes and neurodegeneration, announced today the appointment of distinguished pharmaceutical industry veteran John Amatruda, M.D. to its Scientific Advisory Board. John has a long history in medicine and pharma, including Bayer and Merck & Co, where he was SVP and Franchise Head for Diabetes and Obesity. Under his leadership, the blockbuster drugs Vytorin™, Januvia™, and Janumet™, were approved. “John’s expertise in end-to-end drug development, especially for diabetes …

FDA Action Alert: Merck, Baudax Bio, Alder and Esperion | BioSpace | 2/14/2020

… patients with greater flexibility in their treatment plans across a variety of cancer types, including melanoma where Keytruda is indicated in both the adjuvant and metastatic settings,” said Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories, in July 2019. Baudax Bio’s IV Meloxicam for Moderate to Severe Pain Baudax Bio, headquartered in Malvern, Pennsylvania, has a target action date of February 20 for its New Drug Application (NDA) for …

Mercks KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC) | Financial Buzz | 2/12/2020

… chemotherapy has now demonstrated positive results as both a first-line treatment in the metastatic setting with this trial, and as neoadjuvant therapy in the KEYNOTE-522 trial,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “We look forward to sharing these findings with the medical community at an upcoming congress and discussing them with the FDA and other regulatory authorities.” The KEYTRUDA breast cancer clinical development program encompasses …

Merck & Co.’s Keytruda hits main goal of triple-negative breast cancer study | 2/12/2020

… in combination with chemotherapy, met one of its dual primary endpoints of progression-free survival (PFS) in patients with metastatic triple-negative breast cancer (TNBC) whose tumours expressed PD-L1. Roger Perlmutter, president of Merck Research Laboratories, remarked “we look forward to sharing these findings with the medical community at an upcoming congress and discussing them with the FDA and other regulatory authorities.” The KEYNOTE-355 trial is evaluating Keytruda …

Merck’s Checkpoint Inhibitor Keytruda Hits Another Mark in Breast Cancer | 2/12/2020

… alone. The DMC recommended the trial continue without changes to evaluate the other dual primary endpoint, which is overall survival (OS). “Triple-negative breast cancer is an aggressive malignancy,” said Roger M. Perlmutter , president, Merck Research Laboratories. “It is very encouraging that Keytruda in combination with chemotherapy has now demonstrated positive results as both a first-line treatment in the metastatic setting with this trial, and as neoadjuvant therapy in …

FDA Accepts For Review Supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) | Business Wire | 2/3/2020

… 4, 2020. “This submission reinforces Merck’s continued dedication to researching and developing potential antibiotic treatment options which address unmet medical needs,” said Dr. Nicholas Kartsonis, senior vice president, clinical research, infectious diseases and vaccines, Merck Research Laboratories. “We are unwavering in our commitment to evaluate treatments for infections caused by certain Gram-negative pathogens.” The submission is based on the results of the pivotal Phase 3 RESTORE-IMI 2 trial …

Merck Receives Approval for BELSOMRA® (suvorexant) C-IV Label Update to Include Findings from Study of Insomnia in Patients with Mild-to-Moderate Alzheimer’s Disease | 2/3/2020

KENILWORTH, N.J. – Merck the company has received approval from the U.S. Food and Drug Administration (FDA) for an update to the prescribing information for BELSOMRA ® (suvorexant) C-IV to include findings on its use for the treatment of insomnia in patients with mild-to-moderate Alzheimer’s disease. BELSOMRA is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. “Alzheimer’s disease is often accompanied …

FDA Approves Mercks DIFICID (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older | 1/28/2020

… Associate Medical Director of Infection Prevention and Control at Ann & Robert H. Lurie Children’s Hospital of Chicago. “I am very excited to have a new C. difficile infection treatment option for my pediatric patients.” “ Merck is committed to developing new treatments, as well as expanding indications of existing ones, in order to provide more solutions to treat infectious diseases, particularly among children, ” said Dr. Nicholas Kartsonis, senior vice president, clinical …

FDA Approves Merck’s Dificid (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older | 1/28/2020

Print this page KENILWORTH, N.J.–(BUSINESS WIRE)– Monday, January 27, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the a New Drug Application (NDA) for Dificid ( fidaxomicin ) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium ) difficile -associated diarrhea ( CDAD ) in children aged six months and older. 1 Dificid is a macrolide …

Clinical Research

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC) | 3/7/2020

… Tumors Expressed PD-L1 (CPS ≥10) Data to be Presented at an Upcoming Medical Congress and Discussed with Regulatory Authorities Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that … and healthy cells. Merck has the industry’s largest immuno-oncology clinical research program. There are currently more than 1,000 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program …

KEYNOTE-024 Meets PFS End Point in Patients With Classical Hodgkin Lymphoma | 3/4/2020

… Merck. 1 In addition to demonstrating a PFS benefit, there were no new safety signals observed with pembrolizumab in this study. The overall survival data were immature and therefore not included in the interim analysis.“Patients with classical Hodgkin lymphoma are generally young and when they do not achieve remission following standard treatment, their cancer is challenging to treat,” said Jonathan Cheng, MD, vice president, oncology clinical research, Merck Research …

Population Health

Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite | 3/4/2020

… treatments that will kill the parasite once it’s present inside the human body, and we’re excited to be working with Merck scientists and other leaders in the field to advance this novel class of compounds … and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research …

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) | 3/2/2020

Corporate News Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Data from Pivotal Phase 3 KEYNOTE-204 Study to be Presented … and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research …

Biotech

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is … Crelux Critical Diagnostics Critical Path Institute (C-Path) [US] CTI Biotech Daiichi Sankyo Dako (now part of Agilent) Dana-Farber Cancer Institute [US] Danaher DaVita Labs DiaGenic Durin Technologies DxS (now part of QIAGEN) EKO …

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Benzinga | 12/4/2019

… them from pipeline. Companies Mentioned A. Menarini Industrie Farmaceutiche Riunite Srl AbbVie Inc Actinium Pharmaceuticals Inc ADC Therapeutics SA Aduro BioTech Inc Affimed GmbH Agios Pharmaceuticals Inc AlfaSigma SpA Alissa Pharma Angiocrine Bioscience Inc Anhui … Inc Kite Pharma Inc Magenta Therapeutics Inc Marker Therapeutics Inc Merck & Co Inc Merck KGaA Millennium Pharmaceuticals Inc Miltenyi Biotec GmbH NantKwest Inc NBE-Therapeutics AG NewBio Therapeutics Inc Northlake International LLC OncoTartis Inc Protheragen …

Food and Drug Administration

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is … Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific and Industrial Research Organisation (CSIRO) [ Australia ] EMA (European Medicines Agency) ETH Zurich European Commission European Federation of Pharmaceutical …

Reuters Health News Summary | Yahoo News | 12/4/2019

Roche’s Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb. The U.S. Food and Drug Administration approved Tecentriq mixed with Celgene’s Abraxane and carboplatin chemotherapy to treat metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations …

American Society of Clinical Oncology

Roche’s Tecentriq, chasing Merck’s Keytruda, nabs another nod in all-important lung cancer | FiercePharma | 12/4/2019

Merck & Co.’s Keytruda-chemo pairing. Last April, Merck showed Keytruda in tandem with Eli Lilly’s chemotherapy Alimta and platinum chemo cut the risk of death by half in first-line nonsquamous NSCLC. In an update of that Keynote-189 trial at this year’s American Society of Clinical Oncology meeting, Merck showed patients on the Keytruda regimen lived a median 22 months compared with 10.7 months for those on chemo …

Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer | Business Wire | 12/2/2019

Weather AP Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer 1 hr ago Save BOTHELL, Wash. & TOKYO–(BUSINESS … not intended to constitute an advertisement or medical advice. 1 American Society of Clinical Oncology. Bladder Cancer: Introduction (05-2019). https://www.cancer.net/cancer-types/bladder-cancer/introduction . 2 International Agency for Research on Cancer. Cancer tomorrow …

Biosimilars

Pfizer (NYSE:PFE) versus Eton Pharmaceuticals (NYSE:ETON) Critical Contrast - Transcript Daily | 12/4/2019

… addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima … with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Merck KGaA; licensing agreement with BionTech AG; and collaboration agreements with Merck & Co., Inc. and Eli Lilly & Company, as well as with Merck KGaA and …

Merck Isn’t Too Reliant on Keytruda Yet, and That’s Good News for Investors | 12/4/2019

Merck’s key growth driver may just be getting started. (TMFPBakiny) Dec 3, 2019 at 10:48AM Merck ( NYSE:MRK ) has performed well on the stock market this year. Since early January, the company’s shares are up … selling drug by 2024 as Humira faces stiff competition from biosimilars in Europe. The cancer medicine will likely continue on its upward trajectory and may eventually account for a much larger percentage of Merck’s sales …

Medicare

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is … Foundation [UK] Broad Institute [US] Cancer Research UK Centers for Medicare and Medicaid Services (CMS) [US] Chinese State Food and Drug Administration (SFDA) Commonwealth Scientific and Industrial Research Organisation (CSIRO) [ Australia ] EMA (European Medicines Agency …

Inside The 2019 Forbes Healthcare Summit | 12/4/2019

… attendees will discuss the latest healthcare solutions for the brain, body and business. KENNETH C. FRAZIER Chairman & Chief Executive Officer, Merck & Co., Inc. In a special conversation with Steve Forbes, this inspiring agent of change … future is coming to you. SEEMA VERMA Administrator, Centers for Medicare & Medicaid Services (CMS) Since joining the Trump Administration, Seema Verma has set a bold new agenda, including goals to empower patients and transform healthcare …

CDC

Time to say goodbye to HIV stigma | 12/4/2019

In 1981, the Centers for Disease Control and Prevention (CDC) reported on five previously healthy homosexual men who were sick with an unusual form of pneumonia. The cases stood out because normally, that type of … the disease. And yet, according to a recent survey by Merck and the Prevention Access Campaign, misinformation about AIDS and HIV is still staggeringly prevalent. The survey found that 28 percent of HIV-negative millennials …

Vaccines: A Healthcare Revolution and High Return on Investment | 12/3/2019

… stockpiles of variola, the virus that causes smallpox—in Atlanta, Georgia, at the U.S. Centers for Disease Control and Prevention (CDC) and the Russian State Center for Research on Virology and Biotechnology in Koltsovo, Russia … 4D Pharma , based in Leeds, UK, partnered with U.S.-based Merck to develop Live Biotherapeutics vaccines. Outside the U.S., Merck & Co. is known as MSD. 4D Pharma focuses on the microbiome, the trillions of microorganisms …

Precision Medicine

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is … 2018-2028 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Global Precision Medicine Market Forecast 2019-2029 Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029 Global Protein Expression Market Forecast to 2029 SOURCE Visiongain …

InterVenn Biosciences Releases First-Ever Software for AI-Enabled Mass Spec Analysis | Malvern Daily Record | 12/4/2019

Merck and NASA. To find out more about InterVenn Biosciences and how the company is leveraging artificial intelligence and mass spectrometry to transform medical technology, visit https://intervenn.bio . For all general and media inquiries about InterVenn Biosciences, please contact Andrea Vuturo at [email protected] . About InterVenn Biosciences InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company’s applications include …

National Institutes of Health

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and developments will prevail? • How will the …

Three HIV Vacs For 2021 *All You Need is One to Work and End Game for The Virus | 12/4/2019

… which are “vaccine components designed to induce immune responses against a wide variety of global HIV strains,” according to the National Institutes of Health . “The presumption is that a mosaic is going to give you … say stop the study,” which happened in 2007 when a Merck vaccine trial was shut down after the monitoring board determined that it had no impact on prevention. “None of these vaccines is a particularly …

Merck Research Laboratories

Emilio A. Emini | 3/9/2020

Merck Research Laboratories where he led the biological research that resulted in the development of one of the first highly active antiretroviral therapies for the treatment of HIV infection. As head of vaccine research at Merck beginning in 1996, he led a number of vaccine research programs, including those that resulted in the licensure of the human papillomavirus and human rotavirus vaccines. Prior to joining Wyeth, Emilio also served as …

FDA Action Alert: Horizon, Bristol Myers Squibb, Merck, NewLink, Seattle Genetics and Astellas | 3/9/2020

… Phase I/II CheckMate -040 trial. Data was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Merck and NewLink Genetics’ Ebola Vaccine Ervebo Merck and NewLink Genetics had a BLA under … a unique global partnership,” said Roger M. Perlmutter, president of Merck Research Laboratories, at the time. “In acknowledging this event, I wish in particular to recognize the heroic efforts being made by frontline responders to …

Myriad Genetics

Synthetic Lethality-based Drugs & Targets World Market, Forecast to 2030 by Type of Molecules, Different Target Indications, Synlet Targets, Route of Administration, and Key Geographical Regions | Financial Buzz | 1/9/2020

Merck Ventures Metabomed MetaStat Ministry of Economy and Competitiveness Ministry of Education – Singapore Mission Bay Capital Mission Therapeutics Mitsubishi UFJ Capital Mizuho Capital Moffitt Cancer Center Morgan Noble Morgenthaler Ventures Morphic Therapeutics MPM Capital MS Ventures Mylan Myriad Genetics National Agency for Science and Technology National Cancer Institute National Human Genome Research Institute National Institutes of Health National League Against Cancer National Natural Science Foundation of China National Research Foundation …

Myriad Genetics Test to Identify Cancer Patients Gets FDA Nod | Zacks | 10/28/2019

Myriad Genetics Test to Identify Cancer Patients Gets FDA Nod Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read … side effects.Myriad Genetics announced receiving favorable outcomes from the AstraZeneca/Merck Phase III PROfound study in August 2019. The study met its primary endpoint and demonstrated that men with metastatic castration-resistant prostate (mCRPC) cancer …

Fresenius Kabi

Synthetic Lethality-based Drugs & Targets World Market, Forecast to 2030 by Type of Molecules, Different Target Indications, Synlet Targets, Route of Administration, and Key Geographical Regions | Financial Buzz | 1/9/2020

… Track Initiative Flagship Ventures Fonds de solidarit FTQ Forward Informatics Foundation Medicine Frazier Healthcare Ventures Fred Hutchinson Cancer Research Center Fresenius Kabi Fund for Scientific and Technological Research Georgetown University GIC Google Ventures Grand Angels … project Massachusetts General Hospital Mayo Clinic MD Anderson Cancer Center Merck Ventures Metabomed MetaStat Ministry of Economy and Competitiveness Ministry of Education – Singapore Mission Bay Capital Mission Therapeutics Mitsubishi UFJ Capital Mizuho Capital Moffitt Cancer …

Fresenius Kabi Announces Availability of Fosaprepitant for Injection 150 mg per vial | Business & Finance | manchestertimes.com | Business Wire | 11/13/2019

LAKE ZURICH, Ill.–(BUSINESS WIRE)–Nov 13, 2019– Fresenius Kabi announced today the immediate availability in the United States of Fosaprepitant for Injection 150 mg per vial, the newest addition to the company’s generic oncology … in Bad Homburg, Germany. Emend ® is a registered trademark of Merck and Co. View source version on businesswire.com : https://www.businesswire.com/news/home/20191113005162/en/ CONTACT: Media contact …

Pfizer

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and developments will prevail? • How will the market shares of the regional markets change by 2029 and which geographical region will lead the market in 2029? • Who are the leading players and what …

Multiple Sclerosis Therapeutics Market To Reach USD 25.91 Billion By 2026 | Reports And Data | Globe Newswire | 12/4/2019

… Pfizer, Sanofi-Aventis, Merck, and Novartis, AbbVie Inc., Acorda Therapeutics Inc. To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/multiple-sclerosis-therapeutics-market Segments covered in the report: For the purpose of this report, Reports and Data has segmented the Multiple Sclerosis Therapeutics market on the basis of product type, mode of administration type, distribution channel, and region: Product Type (Revenue …

Novartis

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and developments will prevail? • How will the market shares of the regional markets change by 2029 and which geographical region will lead the market in 2029? • Who are the leading players and what are …

Multiple Sclerosis Therapeutics Market To Reach USD 25.91 Billion By 2026 | Reports And Data | Globe Newswire | 12/4/2019

… Merck, and Novartis, AbbVie Inc., Acorda Therapeutics Inc. To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/multiple-sclerosis-therapeutics-market Segments covered in the report: For the purpose of this report, Reports and Data has segmented the Multiple Sclerosis Therapeutics market on the basis of product type, mode of administration type, distribution channel, and region: Product Type (Revenue, USD Million; 2016 …

GlaxoSmithKline

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Institute for Innovation Foresee Pharmaceuticals Fougera Pharmaceuticals Fuji Pharma Genea Biomedx Genoma Genome Medical German Cancer Research Center Gilead Sciences GlaxoSmithKline GOG Foundation Golden Valley Development Good Start Genetics Grunenthal Guided Therapeutics Gynica Halt Medical … MedImmune Medinova MedTech For Solutions Medtronic Mel-Mont Medical MenoGeniX Merck and Co Merck KGaA Merck Serono Merus Labs International MilanaPharm Millendo Therapeutics Ministry of Health (Turkey) Mission Pharmacal Mithra Pharmaceuticals Mitsubishi Tanabe Pharma Morphic …

Global Cancer Immunotherapy Market: $100+ Billion Analysis & Forecast 2020-2023 - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

GlaxoSmithKline 10.32 Gliknik Inc 10.33 GlobeImmune Inc 10.34 Heat Biologics Inc 10.35 Immatics Biotechnologies GmbH 10.36 ImmunoCellular Therapeutics Ltd. 10.37 Immunocore Ltd. 10.38 ImmunoFrontier Inc 10.39 ImmunoGen Inc 10.40 Immunomedics Inc 10.41 Immunotope Inc 10.42 Immunovaccine Inc 10.43 Inovio Pharmaceuticals Inc 10.44 Janssen Biotech Inc 10.45 Juno Therapeutics Inc 10.46 Kite Pharma Inc 10.47 MabVax Therapeutics Holdings Inc 10.48 MedImmune LLC 10.49 Merck & Co., Inc 10.50 Merrimack Pharmaceuticals Inc 10.51 …

Bristol-Myers Squibb

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and developments will prevail? • How will the …

Reuters Health News Summary | Yahoo News | 12/4/2019

Roche’s Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb. The U.S. Food and Drug Administration approved Tecentriq mixed with Celgene’s Abraxane and carboplatin chemotherapy to treat metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations …

Thermo Fisher

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

Thermo Fisher Scientific • Worldwide Clinical Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and developments …

Polymerase Chain Reaction (PCR) Market - Global Forecast to 2025: Market is Expected to Reach $12.9 Billion - ResearchAndMarkets.com | Malvern Daily Record | 12/4/2019

Merck Kgaa Promega Corporation Qiagen N.V. Takara Bio, Inc. Thermo Fisher Scientific, Inc. For more information about this report visit https://www.researchandmarkets.com/r/xnbnk0 …

Bristol-Myers

Reuters Health News Summary | Yahoo News | 12/4/2019

Roche’s Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb. The U.S. Food and Drug Administration approved Tecentriq mixed with Celgene’s Abraxane and carboplatin chemotherapy to treat metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations …

Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised) | Zacks | 12/4/2019

Bristol-Myers ( BMY - Free Report ) and Merck ( MRK - Free Report ) . You can see the complete list of today’s Zacks 1 Rank (Strong Buy) stocks here . Shares of Roche have gained 22.8% this year so far. Earnings estimates for 2019 have risen 1.2% while the same for 2020 increased almost 2% over the past 60 days. Bristol Myers’ earnings estimates have increased 2.1% and 9.5%, respectively, for 2019 and 2020 over …

AbbVie

Multiple Sclerosis Therapeutics Market To Reach USD 25.91 Billion By 2026 | Reports And Data | Globe Newswire | 12/4/2019

… Merck, and Novartis, AbbVie Inc., Acorda Therapeutics Inc. To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/multiple-sclerosis-therapeutics-market Segments covered in the report: For the purpose of this report, Reports and Data has segmented the Multiple Sclerosis Therapeutics market on the basis of product type, mode of administration type, distribution channel, and region: Product Type (Revenue, USD Million; 2016 …

HealthCare Ventures

Synthetic Lethality-based Drugs & Targets World Market, Forecast to 2030 by Type of Molecules, Different Target Indications, Synlet Targets, Route of Administration, and Key Geographical Regions | Globe Newswire | 1/9/2020

… Epic Sciences EpiCypher European Research Council Fast Track Initiative Flagship Ventures Fonds de solidarit FTQ Forward Informatics Foundation Medicine Frazier Healthcare Ventures Fred Hutchinson Cancer Research Center Fresenius Kabi Fund for Scientific and Technological Research … project Massachusetts General Hospital Mayo Clinic MD Anderson Cancer Center Merck Ventures Metabomed MetaStat Ministry of Economy and Competitiveness Ministry of Education - Singapore Mission Bay Capital Mission Therapeutics Mitsubishi UFJ Capital Mizuho Capital Moffitt Cancer …

Synthetic Lethality-based Drugs & Targets World Market, Forecast to 2030 by Type of Molecules, Different Target Indications, Synlet Targets, Route of Administration, and Key Geographical Regions | Financial Buzz | 1/9/2020

… Epic Sciences EpiCypher European Research Council Fast Track Initiative Flagship Ventures Fonds de solidarit FTQ Forward Informatics Foundation Medicine Frazier Healthcare Ventures Fred Hutchinson Cancer Research Center Fresenius Kabi Fund for Scientific and Technological Research … project Massachusetts General Hospital Mayo Clinic MD Anderson Cancer Center Merck Ventures Metabomed MetaStat Ministry of Economy and Competitiveness Ministry of Education – Singapore Mission Bay Capital Mission Therapeutics Mitsubishi UFJ Capital Mizuho Capital Moffitt Cancer …

SVB Leerink

Roche’s Tecentriq, chasing Merck’s Keytruda, nabs another nod in all-important lung cancer | FiercePharma | 12/4/2019

… population, according to Sandler—because in terms of clinical results, the newly approved Tecentriq-chemo combo is no match for Merck & Co.’s Keytruda-chemo pairing. Last April, Merck showed Keytruda in tandem with Eli … analyst As Roche prepares applications for the use to regulators, SVB Leerink analyst Daina Graybosch has contended it would be hard for Roche to challenge “[t]he lead and loyalty for Keytruda among oncologists treating …

Man Group plc Lowers Stock Position in Merck & Co., Inc. (NYSE:MRK) | 12/4/2019

Posted by ABMN Staff on Dec 4th, 2019 // No Comments Man Group plc lessened its holdings in Merck & Co., Inc. (NYSE:MRK) by 47.5% in the 3rd quarter, according to its most recent filing with … buy” rating in a research note on Tuesday, September 3rd. Svb Leerink assumed coverage on Merck & Co., Inc. in a research note on Friday, August 16th. They set an “outperform” rating and a $103.00 price …

BlackRock Inc.

Merck & Co., Inc. (NYSE:MRK) Receives Average Rating of “Buy” from Analysts - Dakota Financial News | 12/3/2019

Merck & Co., Inc. (NYSE:MRK) Receives Average Rating of “Buy” from Analysts Posted by Thomas Dobrow on Dec 2nd, 2019 // Comments off Shares of Merck & Co., Inc. (NYSE:MRK) have been assigned an average recommendation … 2,038,169,000 after acquiring an additional 23,940,007 shares during the period. BlackRock Inc. boosted its position in shares of Merck & Co., Inc. by 2.3% in the 2nd quarter. BlackRock Inc. now owns 191,863,408 shares of the …

Bank of Hawaii Boosts Stock Position in Merck & Co., Inc. (NYSE:MRK) | 11/30/2019

Bank of Hawaii grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 1.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission … after buying an additional 23,940,007 shares in the last quarter. BlackRock Inc. raised its position in shares of Merck & Co., Inc. by 2.3% in the second quarter. BlackRock Inc. now owns 191,863,408 shares of the …

Goldman Sachs

Research Analysts’ Updated EPS Estimates for December, 3rd (AGR, AUTO, AZN, BBOX, BLND, BNR, BOO, CAL, CEY, CINE) | 12/3/2019

Merck KGaA (FRA:MRK) was given a €94.00 ($109.30) price target by analysts at Goldman Sachs Group Inc. The firm currently has a sell rating on the stock. Mirati Therapeutics (NASDAQ:MRTX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of …

ASX to drop, RBA rate call ahead | 12/2/2019

… Merck, J&J, Walt Disney and Pfizer. Also on the ‘overbought’ list are Microsoft and Apple as well as JPMorgan and Goldman Sachs. The Institute for Supply Management (ISM) said its index of national factory activity dropped 0.2 point to a reading of 48.1 last month. A reading below 50 indicates contraction in the manufacturing sector, which accounts for 11% of the U.S. economy. Advertisement The ISM index needs to …

Morgan Stanley

Merck KGaA (FRA:MRK) Receives Average Rating of “Hold” from Analysts - Transcript Daily | 12/2/2019

Merck KGaA (FRA:MRK) has earned an average rating of “Hold” from the sixteen analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, twelve … rating in a research report on Tuesday, November 19th. Finally, Morgan Stanley set a €96.00 ($111.63) target price on Merck KGaA and gave the stock a “neutral” rating in a research report on Tuesday, September …

Merck & Co., Inc. (NYSE:MRK) Reaches New 12-Month High at $87.99 | 12/2/2019

Merck & Co., Inc. (NYSE:MRK) Reaches New 12-Month High at $87.99 Posted by Cynthia Vaughn on Dec 2nd, 2019 Merck & Co., Inc. (NYSE:MRK)’s share price reached a new 52-week high during … buy” rating in a research note on Tuesday, September 3rd. Morgan Stanley lifted their price target on shares of Merck & Co., Inc. from $90.00 to $95.00 and gave the stock an “overweight” rating in a …

Maxim Group

OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements | Malvern Daily Record | 12/2/2019

… PARTIES RECOGNIZE THE VALUE OF THIS TRANSACTION “Overall from our perspective this was a strategic and ‘smart’ move by management ” – Maxim Group , A Strategic Move by Management; Brings Cash, Optionality and a Great Partner on … of OncoSec Medical Incorporated. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. SIR-Spheres® is a registered trademark of Sirtex Medical US Holdings, Inc. Important Additional Information …

28 Healthcare Stocks Moving In Tuesday’s Pre-Market Session | Benzinga | 10/29/2019

… The most recent rating by Bank of America, on October 17, is at Neutral, with a price target of $37.00. Merck & Co, Inc. (NYSE: MRK ) stock rose 2.7% to $84.40. The market cap seems to … to be at $4.2 million. The most recent rating by Maxim Group, on October 23, is at Buy, with a price target of $1.00. OrganiGram Holdings, Inc. (NASDAQ: OGI ) shares declined 1.1% to $3.60. The …

BelHealth

NavaDerm Partners adds Dan Wechsler as Executive Chairman | PR Newswire | 12/2/2019

NEW YORK NavaDerm Partners (“NavaDerm” or the “Company”), a Northeast-focused dermatology services company and portfolio company of BelHealth Investment Partners (“BelHealth”), a New York -based healthcare private equity firm, announced the appointment of Dan … Pharmaceuticals at Bausch + Lomb. Dan was previously an executive at Merck & Co., Schering-Plough, Pfizer Inc., Melinta Therapeutics, and The Upjohn Company. Dan holds a Master of Philosophy from University of Rochester , as well as …

NavaDerm Partners adds Dan Wechsler as Executive Chairman | The Wapakoneta Daily News | 12/2/2019

… Dec. 2, 2019 /PRNewswire/ – NavaDerm Partners (“NavaDerm” or the “Company”), a Northeast-focused dermatology services company and portfolio company of BelHealth Investment Partners (“BelHealth”), a New York -based healthcare private equity firm, announced the appointment … Pharmaceuticals at Bausch + Lomb. Dan was previously an executive at Merck & Co., Schering-Plough, Pfizer Inc., Melinta Therapeutics, and The Upjohn Company. Dan holds a Master of Philosophy from University of Rochester , as well as …

Alexandria Venture Investments

Week in Review: Pharmaron, a Beijing CRO, Stages $434 Million Hong Kong IPO | 11/30/2019

… biopharmas to discover biomarkers for precision medicine drugs. The funding was led by Vivo Capital, CICC Healthcare Investment Fund and Alexandria Venture Investments. Sichuan Clover Biopharma completed a $43 million Series B round to support … Lin Chong Investment Management and Yuanju Capital. Trials and Approvals Merck/MSD (NYSE: MRK) announced Keytruda, its anti-PD-1 therapy, has been approved by China’s NMPA as a first-line treatment for patients with …

Cancer Therapeutics Market Size to Reach US$ 176 Bn by 2026 | PR Newswire | 11/27/2019

… Astellas Pharma Inc., Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc. among others. The key players of the … Inc. launched with US$50 Mn in financing from 3SBio, Alexandria Venture Investments, 20/20 HealthCare Partners, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital. The launch is intended to …

Alexandria Venture

Week in Review: Pharmaron, a Beijing CRO, Stages $434 Million Hong Kong IPO | 11/30/2019

… biopharmas to discover biomarkers for precision medicine drugs. The funding was led by Vivo Capital, CICC Healthcare Investment Fund and Alexandria Venture Investments. Sichuan Clover Biopharma completed a $43 million Series B round to support … Lin Chong Investment Management and Yuanju Capital. Trials and Approvals Merck/MSD (NYSE: MRK) announced Keytruda, its anti-PD-1 therapy, has been approved by China’s NMPA as a first-line treatment for patients with …

Cancer Therapeutics Market Size to Reach US$ 176 Bn by 2026 | PR Newswire | 11/27/2019

… Astellas Pharma Inc., Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc. among others. The key players of the … Inc. launched with US$50 Mn in financing from 3SBio, Alexandria Venture Investments, 20/20 HealthCare Partners, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital. The launch is intended to …

Citigroup

“The mysterious, super-elite Pilgrim Society.” “The most illustrious world-wide personalities.” | 11/29/2019

… Folger; Field; Fisher; Flagler; Roosevelt; Guggenheim; Gould; McCormick; Berwind; Lehman; Stillman; Baker; Livingston; and others. Top executives and directors of Citigroup; JPMorganChase; BankAmerica; Bank of New York; Wells Fargo; Mellon Bank; American Express; Merrill Lynch … Warner; Verizon Communications; Johnson & Johnson; Pfizer; Eli Lilly; Warner Lambert; Merck & Company; Bristol Myers Squibb; Astra Zeneca; Schering Plough; Glaxo Smith Kline; Pharmacia & Upjohn; United Technologies; Raytheon; Lockheed Martin; Boise Cascade; International Paper; Federal Reserve …

“Karuna 2.0 & Another Nasdaq Record” Vista Partners Daily Market Recap 11/19/19 | 11/20/2019

… All the shares to be sold in the proposed offering will be sold by Karuna. Goldman Sachs & Co. LLC and Citigroup are acting as joint book-running managers for the offering. Stifel, Nicolaus & Company, Incorporated … 4,716.8935 +1.45%. Johnson & Johnson (JNJ) closed at $ 134.82/share -.01%, Merck & Co (MRK) closed at $84.65/share +.62%, Pfizer (PFE) closed at $37.66/share +1.18%. Merck (MRK) reported earnings on 10/29/2019 of $1.51, beating estimates …

Perlmutter Cancer Center

Merck’s Keytruda Gets FDA Approval for High-Risk Bladder Cancer | Equities News | 1/10/2020

Healthcare Life Sciences Cancer Biotechnology Merck’s Keytruda Gets FDA Approval for High-Risk Bladder Cancer Edward Kim Follow Thursday, 09 January 2020 15:27 (EST) According to the American Society of Clinical Oncology, an estimated 80,470 … Medicine and director of Genitourinary Medical Oncology, NYU Langone Health’s Perlmutter Cancer Center. That’s the third bladder cancer indication for which Merck has received approval for KEYTRUDA, further burnishing its blockbuster status. Merck had KEYTRUDA …

FDA Approves Mercks KEYTRUDA (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy | Financial Buzz | 1/9/2020

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment … and director of Genitourinary Medical Oncology at NYU Langone Health’s Perlmutter Cancer Center. “Historically, patients with high-risk, non-muscle invasive bladder cancer with CIS whose cancer is unresponsive to BCG treatment had limited non …

Harvard Medical School

Inside The 2019 Forbes Healthcare Summit | 12/4/2019

… attendees will discuss the latest healthcare solutions for the brain, body and business. KENNETH C. FRAZIER Chairman & Chief Executive Officer, Merck & Co., Inc. In a special conversation with Steve Forbes, this inspiring agent of change … horizon. PAUL FARMER Cofounder, Partners In Health; Kolokotrones University Professor, Harvard Medical School Dr. Paul Farmer has dedicated his life to strengthening health systems and improving healthcare delivery, particularly in resource-poor regions of the …

New Consortium Launched in Partnership with CISCRP to Improve National Clinical Research Literacy | PRWeb | 12/4/2019

… focus energy and resources on community-based education during the next five years beginning in early 2020. Consortium members include Merck, IQVIA, Biogen, Otsuka, CSL Behring, Janssen, WCG, Boston Scientific, EMD Serono, and Pfizer. Representatives … and Engagement (CARE) Research Center at the Massachusetts General Hospital, Harvard Medical School. The Consortium initiative builds on CISCRP’s 18-year experience producing and hosting internationally recognized live educational events – called AWARE-for-ALL programs …

Mayo Clinic

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is … Leuven (University of Leuven) LabCorp Life Technologies LightArray Biotech M2Gen Mayo Clinic [US] Mayo Collaborative Services MDxHealth Medical Research Council [UK] MediMedia Pharma Solutions Memorial Sloan-Kettering Cancer Center [US] Merck & Co. Merck KGaA Metabolon …

Mourners remember West Fargo teen who was ‘always there for everyone’ | 12/4/2019

… was ‘always there for everyone’ Written By: Barry Amundson Dec 3rd 2019 - 9pm. Images of West Fargo Sheyenne sophomore Ben Merck are displayed at Lutheran Church of the Cross in West Fargo on Tuesday, Dec … Ben was diagnosed with ALS in late October at the Mayo Clinic in Rochester, Minn. “He had incredible resilience,” the pastor said. “He had no fear.” Bjerke said that her friend was “one of the …

Massachusetts General Hospital

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is … Consortium (ICGC) Les entreprises du médicament (LEEM) [ France ] Malmö University Massachusetts General Hospital Max Planck Institute for Molecular Genetics [ Germany ] National Academy of Sciences National Cancer Institute (NCI) [US] National Health Service (NHS) [UK] National …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova MedTech For Solutions Medtronic Mel-Mont Medical MenoGeniX Merck and Co Merck KGaA Merck Serono Merus Labs International MilanaPharm Millendo Therapeutics Ministry of Health (Turkey) Mission Pharmacal Mithra Pharmaceuticals Mitsubishi Tanabe Pharma Morphic Therapeutic MSD Mundipharma MyBiotics Pharma Mylan Laboratories Myovant …

MD Anderson Cancer Center

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova MedTech For Solutions Medtronic Mel-Mont Medical MenoGeniX Merck and Co Merck KGaA Merck Serono Merus Labs International MilanaPharm Millendo Therapeutics Ministry of Health (Turkey) Mission Pharmacal Mithra Pharmaceuticals Mitsubishi Tanabe Pharma Morphic Therapeutic MSD Mundipharma MyBiotics Pharma Mylan Laboratories Myovant Sciences Myrtle Potter & Company …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova MedTech For Solutions Medtronic Mel-Mont Medical MenoGeniX Merck and Co Merck KGaA Merck Serono Merus Labs International MilanaPharm Millendo Therapeutics Ministry of Health (Turkey) Mission Pharmacal Mithra Pharmaceuticals Mitsubishi Tanabe Pharma Morphic Therapeutic MSD Mundipharma MyBiotics Pharma Mylan Laboratories Myovant Sciences Myrtle Potter & Company …

University of Rochester

Global Stem Cell Therapy Contract Manufacturing Market Research 2019-2030: Source of Stem Cells, Types of Stem Cells, Size of Contract Service Provider Company, Scale of Operation, Key Regions | PR Newswire | 12/3/2019

Global Stem Cell Therapy Contract Manufacturing Market Research 2019-2030: Source of Stem Cells, Types of Stem Cells, Size of Contract Service Provider Company, Scale of Operation, Key Regions News provided by Research and Markets Dec 03, 2019, 12:00 ET DUBLIN , Dec. 3, 2019 /PRNewswire/ – The “Stem Cell Therapy Contract Manufacturing Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering. The Stem Cell Therapies Contract Manufacturing Market, 2019 - 2030 report features …

NavaDerm Partners adds Dan Wechsler as Executive Chairman | PR Newswire | 12/2/2019

Merck & Co., Schering-Plough, Pfizer Inc., Melinta Therapeutics, and The Upjohn Company. Dan holds a Master of Philosophy from University of Rochester , as well as a B.A. from the State University of New York at Brockport . Dan stated, “I am excited to join NavaDerm and help support Dr. Murphy and our outstanding physician partners in building a world class dermatology platform. NavaDerm’s focus on providing superior clinical care and partnering …

UPMC

Bladder cancer drug shortage has ‘caused deaths,’ UPMC urologist says | Becker’s Hospital Review | 12/2/2019

The worsening shortage of a bladder cancer drug solely manufactured by Merck has undoubtedly led to deaths, Pittsburgh urologist Ben Davies, MD, told CNBC . The shortage of Tice BCG, a biologic drug that is remarkably … has definitely led to poor outcomes in bladder cancer patients,” UPMC urologist Dr. Davies said. “You just get more recurrences. So that means you have to have more surgeries, you have to come back to …

Transcript: Nightly Business Report – November 27, 2019 | Nightly Business Report | 11/28/2019

UPMC UROLOGIC ONCOLOGIST: It was the first and still the most effective immunotherapy for cancer, and with BCG, we have about 70 percent success rate in obliterating hybrid cells. TIRRELL: But theres a shortage, one thats been going on for years, originally made by Sanofi and Merck (NYSE:MRK), after a manufacturing issue at a Sanofi Pasteur facility in 2012, that company stopped making BCG in 2016. And …

University of Texas MD Anderson Cancer Center

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | The Wapakoneta Daily News | 11/28/2019

… Mayo Clinic MD Anderson Cancer Center Medical College of Wisconsin Medigene MedImmune Medisix Therapeutics MeiraGTx Memorial Sloan Kettering Cancer Center Merck Mesoblast Microsynth Mie University Hospital Milo Biotechnology Miltenyi Biotec Minerva Biotechnologies MingJu Therapeutics Mirimus … University of Pennsylvania University of Southern California University of Technology University of Texas MD Anderson Cancer Center University of Zurich Unum Therapeutics Uppsala University Urovant Sciences UT Southwestern Medical Center V Foundation ValueAct Capital Management …

UT Southwestern Medical Center

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | The Wapakoneta Daily News | 11/28/2019

… Mayo Clinic MD Anderson Cancer Center Medical College of Wisconsin Medigene MedImmune Medisix Therapeutics MeiraGTx Memorial Sloan Kettering Cancer Center Merck Mesoblast Microsynth Mie University Hospital Milo Biotechnology Miltenyi Biotec Minerva Biotechnologies MingJu Therapeutics Mirimus … Center University of Zurich Unum Therapeutics Uppsala University Urovant Sciences UT Southwestern Medical Center V Foundation ValueAct Capital Management VBL Therapeutics VCN Biosciences Vector Neurosciences VectorBuilder Velaz Vertex Pharmaceuticals Verve Therapeutics Vessl Vigene Biosciences Virttu …

Moffitt Cancer Center

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | The Wapakoneta Daily News | 11/28/2019

Merck Mesoblast Microsynth Mie University Hospital Milo Biotechnology Miltenyi Biotec Minerva Biotechnologies MingJu Therapeutics Mirimus Moffitt Cancer Center MolMed Momotaro-Gene Monsanto MultiVir Mustang Bio Myonexus Therapeutics Nagoya University Nanfang Hospital of Southern Medical University Nanjing Children’s Hospital Nanjing Legend Biotech NanoCor Therapeutics Nanogenics Nanosens Innovations National Cancer Institute National Eye Institute National Heart, Lung, and Blood Institute National Human Genome Research Institute National Institute of Aging National Institute of …

Humana

Stocks That Hit 52-Week Highs On Wednesday | 12/4/2019

Wednesday’s morning session saw 124 companies set new 52-week highs. Highlights: Merck & Co (NYSE: MRK ) was the largest company by market cap to set a new 52-week high. Orthometrix (OTC: OMRX ) was the … the day, having made a 52-week high of $14.57. Humana (NYSE: HUM ) stock on Wednesday broke to a yearly high of $345.84. Shares traded up 0.98%. Kao (OTC: KAOOY ) stock made a new 52 …

Nov 29, 2019 - Orbimed Advisors Llc Buys Prevail Therapeutics Inc, SpringWorks Therapeutics Inc, LogicBio Therapeutics Inc, Sells Agilent Technologies Inc, Boston Scientific Corp, Bristol-Myers Squibb Company - GuruFocus.com | 11/29/2019

New York, NY, based Investment company Orbimed Advisors Llc ( Current Portfolio ) buys Prevail Therapeutics Inc, SpringWorks Therapeutics Inc, LogicBio Therapeutics Inc, Humana Inc, BELLUS Health Inc, sells Agilent Technologies Inc, Boston Scientific Corp, Bristol-Myers Squibb Company, Merck Inc, Illumina Inc during the 3-months ended 2019Q3, according to the most recent filings of the investment company, Orbimed Advisors Llc. As of 2019Q3, Orbimed Advisors Llc owns 115 stocks with …

Cigna

Tech Data Leaps (+12.32%) On Apollo Bid & Broad Markets Take It On Chin! Vista Partners Daily Market Recap 11/29/19 | 11/30/2019

… per share. Recently reports surfaced that publicly traded private equity firm KKR (KKR $29.49, -.94%) is preparing a buyout plan. Cigna (CI) closed at $199.92/share, -.05%. INVO Bioscience, Inc. (IVOB), a medical device company … 4,999.97, -.26%. Johnson & Johnson (JNJ) closed at $ 137.49/share, -.19%, Merck & Co (MRK) closed at $87.18/share, -.49%, Pfizer (PFE) closed at $38.52/share, -.28%. Merck (MRK) reported earnings on 10/29/2019 of $1.51, beating estimates …

Unexpected Key Data Points, AVX Corp (+18.97%), INVO Bioscience (+9.09%) & Broad Markets Rise! Vista Partners Daily Market Recap 11/27/19 | 11/28/2019

Cigna (CI) closed at $200.03/share, -.17%. Biotech The Ishares Nasdaq Biotechnology ETF (IBB) moved up +.77% closing at $119.39 & the NYSE Arca Biotech Index (^BTK) closed at 5,012.99, +1.16%. Johnson & Johnson (JNJ) closed at $ 137.75/share, +.42%, Merck & Co (MRK) closed at $87.61/share, +.31%, Pfizer (PFE) closed at $38.63/share, +.89%. Merck (MRK) reported earnings on 10/29/2019 of $1.51, beating estimates of $1.28 per share. Pfizer (PFE) reported …

WellCare Health

The 2019 CPA-Zicklin Index of Corporate Political Disclosure and Accountability | 11/12/2019

Merck & Co. Inc.; Microsoft Corp.; Mondelez International Inc.; Morgan Stanley; MSCI Inc.; Noble Energy Inc.; Norfolk Southern Corp.; Prudential Financial Inc.; Qualcomm Inc.; Regeneron Pharmaceuticals Inc.; Regions Financial Corp.; Salesforce.com Inc.; Sempra Energy; State Street Corp.; Tiffany & Co.; Tractor Supply Co.; U.S. Bancorp; Union Pacific Corp.; United Parcel Service Inc.; United Technologies Corp.; UnitedHealth Group Inc.; Unum Group; Visa Inc.; Walgreens Boots Alliance Inc.; WellCare Health Plans, Inc.; and The …

Merger Arbitrage Mondays - 2 New Acquisitions At Huge Premiums | Seeking Alpha | 9/24/2019

… the United States (“CFIUS”) stating that CFIUS has completed its review of the previously announced proposed acquisition of Versum by Merck KGaA ( OTCPK:MKGAF ) ( OTCPK:MKGAY ), Darmstadt, Germany and has concluded that there are no … Management. On September 19, 2019, Centene Corporation (NYSE: CNC ) and WellCare Health Plans (NYSE: WCG ) announced that insurance departments of 17 states have approved Centene’s pending acquisition of WellCare . On September 20, 2019, II-VI …

UnitedHealthcare

The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health | 11/11/2019

… and the financial markets. Stocks recently featured in the blog include: Mastercard ( MA - Free Report ) , UnitedHealth Group ( UNH - Free Report ) , Merck ( MRK - Free Report ) , Qualcomm ( QCOM - Free Report ) and CVS Health ( CVS - Free Report ) . Here … the back of higher revenues, and strength in both segments, UnitedHealthcare and Optum. However, slowdown of growth in international operations and underperformance in Medicaid business are some concerns. Merck ’s shares have declined 1.9% over …

Tufts Health Plan

CFO Moves – week ending November 1, 2019 | 11/4/2019

… oversight to CFO through various finance roles as the company grew and was acquired. He is a board member for Tufts Health Plan Board of Directors. NetAbstraction, Inc. [CHANTILLY, VA] announced that Ron Kolson has … W. Baird & Co., Inc. He also spent nine years with Merck & Co. in roles of increasing responsibility within the manufacturing division. Sandspring Resources Ltd. [DENVER AND VANCOUVER, British Columbia] (TSX-V: SSP, OTCQX: SSPXF) appointed …

CEO Action For Diversity & Inclusion™ Convenes C-Suite Leaders To Strengthen Companies’ Diversity And Inclusion Strategies | PR Newswire | 1/17/2018

… to lead with action-oriented steps and drive diversity and inclusion commitments. The summit was hosted by global biopharmaceutical company, Merck & Co., Inc. “This business community is united in our dedication to further weaving diversity … The MITRE Corporation, The New York Times , TIAA, TPG Global, Tufts Health Plan, UMB Financial, Unilever, University of Arkansas , University of Dayton , UPS, VF Corporation, Visa, Weil, Gotshal & Manges, Welbilt, Wellcare, Wells Fargo, WPP, XL …

Molina Healthcare

WRL for Nov 2 | 11/2/2019

… 36.41 0.41 ▲ 1 -1.35% McDonald’s Corp MCD 193.94 208.61 -2.97 ▼ 1 0.53% 3M Co MMM 170.09 171.84 -1.28 ▲ 27 11.19% Merck & Co MRK 84.94 81.50 0.05 ▼ 26 8.16% Microsoft MSFT 143.72 129.34 2.47 ▲ 41 34.63 … 37 26.47% MAXIMUS Inc MMS 75.80 73.72 0.46 ▼ 12 0.50% Molina Healthcare MOH 118.83 127.73 -2.98 ▲ 13 6.84% Medical Properties Trust MPW 20.82 18.82 5.84 ▲ 17 14.02% pP Monolithic Power Systems MPWR 155.58 141.82 0.46 …

Earnings Scheduled For October 29, 2019 | 10/29/2019

… billion. Kellogg Company (NYSE: K ) is estimated to report quarterly earnings at $0.91 per share on revenue of $3.35 billion. Merck & Co., Inc. (NYSE: MRK ) is expected to report quarterly earnings at $1.24 per share … earnings at $0.55 per share on revenue of $2.38 billion. Molina Healthcare, Inc. (NYSE: MOH ) is projected to post quarterly earnings at $2.72 per share on revenue of $4.14 billion. Edison International (NYSE: EIX ) is …

Aetna

Health Briefs | Health | phillytrib.com | 10/29/2019

… most vulnerable patients in the community by reducing hospitalizations and emergency room visits. Children’s Crisis Treatment Center wins grant from Aetna The Philadelphia-based Children’s Crisis Treatment Center (CCTC) received a $20,000 grant from Aetna … to community organizations through the 2019 Voices of Health competition. Merck hosts screening of diabetes documentary Merck will host an exclusive screening of the documentary, A Touch of Sugar on Nov. 2 during the annual …

Work begins on quality measurement system for addiction treatment programs | Crain’s New York Business | 10/25/2019

Merck Ventures. Progyny CEO David Schlanger will own 4.3% of the company. —Jonathan LaMantia Payment recommendations for social determinants unveiled at congressional briefing The National Quality Forum, with support from the Aetna Foundation, on Thursday released guidelines to advance quality and payment innovation when it comes to social determinants of health. Five recommendations, developed with participation from dozens of organizations nationally, were unveiled at a bipartisan congressional briefing in Washington …

Oscar Health

Work begins on quality measurement system for addiction treatment programs | Crain’s New York Business | 10/25/2019

… shareholder, owning 25% of the company. Other major shareholders include venture capital firm Kleiner Perkins, a subsidiary of GlaxoSmithKline and Merck Ventures. Progyny CEO David Schlanger will own 4.3% of the company. —Jonathan LaMantia Payment … largest damages owed is about $70.5 million to Manhattan-based Oscar Health. CORRECTION: Onegevity is part of Thorne, a company that sells nutritional supplements and markets testing of consumers’ gut health and genetics. Thorne’s name …

Obamacare Plans Are Turning a Profit: Brainstorm Health | Fortune | 8/23/2019

… a profit in 2019, and certain insurers are continuing to double down on them in spite of said political bedlam. Oscar Health, the startup that has largely placed its bet on the individual insurance market … by HHS, was challenged by large drug makers such as Merck, Eli Lilly, and Amgen, who argued that it would violate free speech rights by compelling such disclosures. GSK’s long-acting HIV injection may only …

Health Net

More than 1 year into Ebola outbreak, DRC facing ‘a new normal’ | 10/23/2019

… has been complicated by governmental and social dynamics, said Majid Sadigh, MD, director of global health for the Western Connecticut Health Network and University of Vermont Larner College of Medicine and the first chief medical … Although insecurity remains a major hurdle to ending the outbreak, Merck’s experimental Ebola virus vaccine V920 has helped contain it. The vaccine has proved more than 97% effective, according to a preliminary estimate. Merck announced …

Anthem

Oct 15, 2019 - Reilly Financial Advisors, Llc Buys Prudential Financial Inc, Sanmina Corp, PRA Health Sciences Inc, Sells Pfizer Inc, Anthem Inc, BB&T Corp - GuruFocus.com | 10/15/2019

La Mesa, CA, based Investment company Reilly Financial Advisors, Llc ( Current Portfolio ) buys Prudential Financial Inc, Sanmina Corp, PRA Health Sciences Inc, Merck Inc, SPDR Barclays Investment Grade Floating Rate ETF, sells Pfizer Inc, Anthem Inc, BB&T Corp, Arrow Electronics Inc, WEC Energy Group Inc during the 3-months ended 2019Q3, according to the most recent filings of the investment company, Reilly Financial Advisors, Llc. As of 2019Q3, Reilly …

Oct 15, 2019 - Bowling Portfolio Management LLC Buys Merck Inc, Microsoft Corp, Xerox Holdings Corp, Sells Chevron Corp, Xerox Holdings Corp, Anthem Inc - GuruFocus.com | 10/15/2019

Cincinnati, OH, based Investment company Bowling Portfolio Management LLC ( Current Portfolio ) buys Merck Inc, Microsoft Corp, Xerox Holdings Corp, Lockheed Martin Corp, Philip Morris International Inc, sells Chevron Corp, Xerox Holdings Corp, Anthem Inc, The Hartford Financial Services Group Inc, Synchrony Financial during the 3-months ended 2019Q3, according to the most recent filings of the investment company, Bowling Portfolio Management LLC. As of 2019Q3, Bowling Portfolio Management LLC owns …

John Amatruda

Neurodon Corporation Announces the Addition of John Amatruda, M.D., Former Head of Diabetes and Obesity at Merck & Co, to its Scientific Advisory Board | 2/17/2020

United States, Indiana, Crown Point – 02-17-2020 ( PRDistribution.com ) — Neurodon Corporation ( https://www.neurodon.net ), a pharmaceutical company engaged in the discovery and development of disease-modifying therapeutics for diabetes and neurodegeneration, announced today the appointment of distinguished pharmaceutical industry veteran John Amatruda, M.D. to its Scientific Advisory Board. John has a long history in medicine and pharma, including Bayer and Merck & Co, where he was SVP and Franchise Head for Diabetes and Obesity …

Fractyl Appoints Senator William W. Bradley and Dr. John Amatruda to the Company’s Board of Directors | PR Newswire | 11/30/2017

Fractyl Appoints Senator William W. Bradley and Dr. John Amatruda to the Company’s Board of Directors LEXINGTON, Mass. - Fractyl Laboratories Inc. ( Fractyl ) today announced the appointment of Senator William W. Bradley and Dr. John Amatruda … drug discovery at Bayer and drug discovery and development at Merck for a number of programs, including metabolism, diabetes, obesity, atherosclerosis and cardiovascular disease, which resulted in five new drug applications. He holds several patents …

Scot Ebbinghaus

Merck’s Keytruda Gets FDA Approval for High-Risk Bladder Cancer | Equities News | 1/10/2020

Healthcare Life Sciences Cancer Biotechnology Merck’s Keytruda Gets FDA Approval for High-Risk Bladder Cancer Edward Kim Follow Thursday, 09 January 2020 15:27 (EST) According to the American Society of Clinical Oncology, an estimated 80,470 … patient population that previously had limited FDA-approved therapies available. -Scot Ebbinghaus, MD, vice president, clinical research, Merck Research Laboratories. While some analysts have voiced concern about the growth trajectory of Merck’s wonder drug, Barron’s …

FDA Approves First New Bladder Cancer Treatment in 20 Years | 1/9/2020

… 20 Years By Print The Food and Drug Administration ( FDA ) granted approval for pembrolizumab—marketed as Keytruda and manufactured by Merck—as an alternative to radical surgery in certain bladder cancer patients. The anti-PD … patients with high-risk, non-muscle invasive bladder cancer,” said Scot Ebbinghaus, MD, vice president, clinical research, Merck Research Laboratories, in a press release from the company. “As the first anti-PD-1 therapy approved …

Donald Trump

Yahoo! News: World News | 12/4/2019

… Israel to UN: Uprooted Jews should be seen as refugees Tariff Man Back, ECB Negative Risk, Lowflation Spreads: Eco Day Merck Cyberattack’s $1.3 Billion Question: Was It an Act of War? Nato summit: Leaders arrive … Tuesday released its report on the impeachment inquiry into President Donald Trump, a day before the House Judiciary Committee holds its first hearing on constitutional issues. The report is here.Here are the latest developments:Intelligence …

Google Alert - stock | 12/3/2019

… tweets, dour PMI data Reuters NEW YORK (Reuters) - The dollar and global stock markets retreated on Monday after U.S. President Donald Trump said he would restore tariffs on … Flag as irrelevant Netflix Stock Is Down … morning to hit a new 52-week … Flag as irrelevant Merck Stock Gains as FDA Accelerates Review of New Use for Blockbuster Cancer Drug Barron’s Merck stock got a modest lift as the pharmaceutical company …

Sara Peerun

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… new report today you stay better informed and ready to act. To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-biomarkers … collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the …

Visiongain Report Offers Transformative Insights on the $11bn Biological Drug API Manufacturing Market | PR Newswire | 12/3/2019

… market forecast to 2029 • Biological Drug API Manufacturing Services market forecast to 2029 by Expression Systems: • Mammalian cell culture • Microbial fermentation • Other expression platforms To request sample pages from this report please contact Sara Peerun at or refer to our website: https://www.visiongain.com/report/biological-drug-api-manufacturing-services-world-industry-and-market-forecast-to-2029/ download_sampe_div • Biological Drug API Manufacturing Services market forecast to 2029 by Therapeutic …

Kenneth C. Frazier

Inside The 2019 Forbes Healthcare Summit | 12/4/2019

… KENNETH C. FRAZIER Chairman & Chief Executive Officer, Merck & Co., Inc. In a special conversation with Steve Forbes, this inspiring agent of change will showcase what he’s achieved throughout his career and preview what he continues to build in his next chapter. JUDITH FAULKNER Chief Executive Officer & Founder, Epic Judy Faulkner started Epic in 1979 in a basement with $70,000 and two part-time assistants. Without venture capital or going public …

American Institute of Chemical Engineers Applauds Organizations and Leaders for “Doing a World of Good” | Globe Newswire | 12/4/2019

Gala showcases health care and sustainability initiatives of Merck & Company and Procter & Gamble Company; awards Doing a World of Good Medal to Jay D. Keasling, metabolic engineering innovator December 04, 2019 08:26 ET Source: AIChE photo-release Merck & Company, represented by Chairman and Chief Executive Officer Kenneth C. Frazier (left), and Procter & Gamble Company, represented by Chairman, President and Chief Executive Officer David S. Taylor (right), received honors at the …

Peter Lynch

Bayer and Teva Double Down on Worst M&A Deals of Decade | 12/4/2019

Peter Lynch Chart of BAYN Bayer’s other big swing and miss was the 2014 acquisition of Merck’s ( MRK ) consumer health business for more than $14 billion. At the time the papers were signed, the deal appeared to be a winner. Bayer was looking for a business much less risky than drugs, but the franchise failed to meet its quest for stability. Four years post-deal, Bayer jettisoned two of the …

Intec Pharma Announces $10 Million Ordinary Shares Purchase Agreement With Aspire Capital - GuruFocus.com | 12/3/2019

… NAS:NTEC. Click here to check it out. NAS:NTEC 30-Year Financial Data The intrinsic value of NAS:NTEC Peter Lynch Chart of NAS:NTEC “We are delighted to partner with Aspire Capital under … Capital. “The company’s collaborations with leading pharma companies such as Merck and Novartis further enhance our confidence in the AP platform’s broad applicability beyond Parkinson’s disease, where the company has already demonstrated proof-of-concept …

Warren Buffett

Yahoo! News: World News | 12/4/2019

… Israel to UN: Uprooted Jews should be seen as refugees Tariff Man Back, ECB Negative Risk, Lowflation Spreads: Eco Day Merck Cyberattack’s $1.3 Billion Question: Was It an Act of War? Nato summit: Leaders arrive … risk at all. Few people understand risk as well as Warren Buffett, who’s built conglomerate Berkshire Hathaway Inc.—and one of the world’s biggest personal fortunes—on the back of insurance companies such as Geico …

Merck cyberattack’s $1.3B question: Was it an act of war? | 12/4/2019

By the time Deb Dellapena arrived for work at Merck & Co.’s 90-acre campus north of Philadelphia, there was a handwritten sign on the door: The computers are down. It was worse than it … risk at all. Few people understand risk as well as Warren Buffett, who’s built conglomerate Berkshire Hathaway Inc. — and one of the world’s biggest personal fortunes — on the back of insurance companies such as Geico …

Melinda Gates

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Scientific Bavarian Nordic Bayer Bayer Healthcare Baylor College of Medicine Beckman Coulter Beijing Genomics Institute (BGI) Besins Healthcare Bill and Melinda Gates Foundation Biocon Biomnis Biotech Inc BL&H Bluebird Bio BMV Medica Boston Scientific … MedImmune Medinova MedTech For Solutions Medtronic Mel-Mont Medical MenoGeniX Merck and Co Merck KGaA Merck Serono Merus Labs International MilanaPharm Millendo Therapeutics Ministry of Health (Turkey) Mission Pharmacal Mithra Pharmaceuticals Mitsubishi Tanabe Pharma Morphic …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

… Scientific Bavarian Nordic Bayer Bayer Healthcare Baylor College of Medicine Beckman Coulter Beijing Genomics Institute (BGI) Besins Healthcare Bill and Melinda Gates Foundation Biocon Biomnis Biotech Inc BL&H Bluebird Bio BMV Medica Boston Scientific … MedImmune Medinova MedTech For Solutions Medtronic Mel-Mont Medical MenoGeniX Merck and Co Merck KGaA Merck Serono Merus Labs International MilanaPharm Millendo Therapeutics Ministry of Health (Turkey) Mission Pharmacal Mithra Pharmaceuticals Mitsubishi Tanabe Pharma Morphic …

Seema Verma

Inside The 2019 Forbes Healthcare Summit | 12/4/2019

… attendees will discuss the latest healthcare solutions for the brain, body and business. KENNETH C. FRAZIER Chairman & Chief Executive Officer, Merck & Co., Inc. In a special conversation with Steve Forbes, this inspiring agent of change … how the drugstore of the future is coming to you. SEEMA VERMA Administrator, Centers for Medicare & Medicaid Services (CMS) Since joining the Trump Administration, Seema Verma has set a bold new agenda, including goals to …

Seventh Annual U.S. News Healthcare of Tomorrow Conference Spotlights Key Insights for Industry Leaders | PR Newswire | 11/22/2019

… and care in this country.” Healthcare of Tomorrow featured a wide range of prominent speakers, including a fireside chat with Seema Verma , Administrator of the Centers for Medicare & Medicaid Services, who shared perspective on the … Mayo Clinic, Nemours, Intuitive Surgical, UT Southwestern, AdventHealth, Fujifilm Healthcare, Merck, Surescripts, CommonSpirit, HDR, and Sutter Health among others . Industry professionals interested in learning more about U.S. News Healthcare of Tomorrow can visit U.S. News …

Michael J. Fox

Visiongain Report Provides Critical Market-led Data on the 57bn Biomarkers Market | PR Newswire | 12/4/2019

… Trials (WWC) • WuXi PharmaTec • Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs: • Pfizer • Novartis • Roche Diagnostics • Ventana Medical Systems • Merck & Co. • Sanofi • GSK • Abbott Laboratories • AstraZeneca • Key questions answered by this report: • How is the biomarkers market evolving? • What is driving and restraining the biomarker market dynamics? • Which trends and developments will prevail? • How will the …

Global Stem Cell Therapy Contract Manufacturing Market Research 2019-2030: Source of Stem Cells, Types of Stem Cells, Size of Contract Service Provider Company, Scale of Operation, Key Regions | PR Newswire | 12/3/2019

Global Stem Cell Therapy Contract Manufacturing Market Research 2019-2030: Source of Stem Cells, Types of Stem Cells, Size of Contract Service Provider Company, Scale of Operation, Key Regions News provided by Research and Markets Dec 03, 2019, 12:00 ET DUBLIN , Dec. 3, 2019 /PRNewswire/ – The “Stem Cell Therapy Contract Manufacturing Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering. The Stem Cell Therapies Contract Manufacturing Market, 2019 - 2030 report features …